At least one solution is to use dry ice.
With the first COVID-19 vaccines due to reach patients in a matter of weeks—including some that require cold storage down to -80º C (-112º F)—companies that manufacture freezers are scrambling to keep up with surging customer demand.
www.genengnews.com
Two leading COVID-19 vaccine candidates poised for release are mRNA-based. Pfizer and BioNTech’s BNT162b2, the leading candidate in the companies’
BNT162 vaccine program, requires shipping and storage at -70º C. Pfizer and BioNTech—which on Friday
requested authorization of BNT162b2 for emergency use—say they have developed temperature-controlled thermal shippers using dry ice to maintain temperature conditions of between -70º C and +10º C.
The shippers can be used as temporary storage units for 15 days by refilling with dry ice. Once thawed, the vaccine can be refrigerated for five days. Each shipper contains a GPS-enabled thermal sensor to track the location and temperature of each vaccine shipment across their pre-set routes leveraging Pfizer’s broad distribution network.